Home > Cardiology > FDA approves Bristol Myers’ oral heart disease drug

FDA approves Bristol Myers’ oral heart disease drug

Reuters - 29/04/2022 - Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration (FDA) approved its oral heart disease drug Mavacamten, making it the first cardiac myosin inhibitor to be permitted for use in the country. Mavacamten, which Bristol Myers acquired in its $13 billion buyout of MyoKardia in 2020, will be used in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is an inherited condition characterized by thickening of heart muscles, which is a common cause of sudden cardiac arrest in young people. About one in every 500 people in the United States suffers from hypertrophic cardiomyopathy, according to the American Heart Association, with a large portion having obstructive hypertrophic cardiomyopathy. The wholesale acquisition cost (WAC) per capsule price of Mavacamten is about $245.20. The monthly list price is $7,356....

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on